Cargando…
Pazopanib in rare histologies of metastatic soft tissue sarcoma
BACKGROUND: Uncommon histopathological subtypes account for less than 5% cases of soft tissue sarcoma (STS) and unclassified STSs comprise another 16%, these are often chemotherapy-resistant, with a dismal outcome in unresectable/metastatic disease. Prospective studies on the use of pazopanib in thi...
Autores principales: | Kataria, Babita, Sharma, Aparna, Biswas, Bivas, Bakhshi, Sameer, Pushpam, Deepam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580588/ https://www.ncbi.nlm.nih.gov/pubmed/34824604 http://dx.doi.org/10.3332/ecancer.2021.1281 |
Ejemplares similares
-
Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
por: Pushpam, Deepam, et al.
Publicado: (2020) -
Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013) -
Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012) -
Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019) -
Paediatric chronic myeloid leukaemia: Is it really a different disease?
por: Pushpam, Deepam, et al.
Publicado: (2019)